Go to search feature Go to content

SEB biotech fund now accessible to Swedish fund savers

Customers in the Nordic markets can now begin saving in the SEB Invest Concept Biotechnology Fund. The fund is global, with a focus on the US. It was opened in autumn 2000 for savers in the German market.
 
The investment focus of the biotech fund is biotech companies engaged in research, development and production. It also is oriented towards companies that distribute biotechnology and bio-medicines as well as industries that can benefit from developments in the biotech sector.
 
"Biotech is a narrow industry with high growth potential. Accordingly, it is important to think long term in your savings. We recommend an investment horizon of five years and that the fund comprise a maximum of 5 to 10 percent of the total portfolio," says Jan Palmberg, Head of Funds, SEB Invest.
 
The responsible manager is Henrietta Theorell, who also manages the SEB Pharmaceutical and Biotech Fund.
 
SEB Invest Concept Biotechnology Fund is a high-risk fund and, accordingly, is presented with a warning triangle.
 
The management fee is 1.5 percent and the start price at 16 October 2000 was EUR 45.00. The fund is registered in Luxembourg.